Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases

OBJECTIVE: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL...

Descripción completa

Detalles Bibliográficos
Autores principales: Deveci, Mehmet Ali, Paydaş, Semra, Gönlüşen, Gülfiliz, Özkan, Cenk, Biçer, Ömer Sunkar, Tekin, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Association of Orthopaedics and Traumatology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197547/
https://www.ncbi.nlm.nih.gov/pubmed/27784623
http://dx.doi.org/10.1016/j.aott.2016.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197547/
https://www.ncbi.nlm.nih.gov/pubmed/27784623
http://dx.doi.org/10.1016/j.aott.2016.03.004

Ejemplares similares